A Durham startup believes it has developed technology that provides alternatives to drugs for treatment of disorders such as ADHD has raised $700,000.

NeuroPlus, aiming to improve cognitive skills, shared its story at the CED Tech Venture Conference in Raleigh earlier this week.

Thirteen investors are backing NeuroPlus, according to an SEC filing.

The company wants to raise $1 million in all.

On Thursday NeuroPlus also launched a Kickstarter fundraising campaign with a goal of $100,000. More than $12,000 has already been committed.

“NeuroPlus has developed brain-sensing technology to help children and adults improve their cognitive skills. Our users wear a headset that measures their brain activity and play brain-controlled video games that train focus and self-control,” CEO Jake Stauch told WRAL TechWire recently for a company profile.

“A randomized, controlled, blinded study found NeuroPlus to be 300% more effective than traditional interventions in reducing inattention, impulsivity, and hyperactivity.”

The device technology, which comes in a headband, already has drawn more than $1 million from a variety of investors.

“There are few evidence-based interventions to help these kids, and many families are hesitant to use medications due to concerns over side effects and other risks,” Stauch explains.

“NeuroPlus is a safe, effective, and engaging training tool to help these children develop critical attention skills.”

The startup said it had raised some $1.2 million before the CED conference.

Profile: NeuroPlus

​

  • Website: http://www.neuro.plus
  • Email conact: jake@neuro.plus
  • Address: 201 W. Main St. #211 Durham, NC 27701
  • CEO: Jake Stauch
  • Video link: https://www.youtube.com/watch?v=DprO3ZJZCsc&feature=youtu.be
  • How many employees? 7 full time, several part-time & contractors
  • Link to CED Tech Venture Company Profile: https://cednc.org/company-profile/neuroplus

The Q&A:

  • What is the focus of your business?

NeuroPlus has developed brain-sensing technology to help children and adults improve their cognitive skills. Our users wear a headset that measures their brain activity and play brain-controlled video games that train focus and self-control.

A randomized, controlled, blinded study found NeuroPlus to be 300% more effective than traditional interventions in reducing inattention, impulsivity, and hyperactivity.

  • What is the top pain point/business application you are seeking to address?

We are currently focused on selling to families of children with attention issues like ADHD.

There are few evidence-based interventions to help these kids, and many families are hesitant to use medications due to concerns over side effects and other risks.

NeuroPlus is a safe, effective, and engaging training tool to help these children develop critical attention skills.

  • What makes it unique?

We’re the only non-pharmacological product on the market that’s clinically proven to improve attention and self-control.

  • Why should investors be interested in your firm?

Last year $14 billion was spent on ADHD medications that parents hate giving to their children. What if there were an alternative that was safer, more effective, and actually fun to use? NeuroPlus is that alternative.

  • How are you financed at this point?

We’ve raised about $1.2 M from Splashpond Investors in Charlotte, Triangle Angel Partners, Capital A Partners, RTP Capital, and several individual angels from around the country.